Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy

Brain, Behavior, and Immunity

Volumn 26, Issue 5, 2012, Pages 699-705

  Wang, Xin Shelley ^a   Williams, Loretta A ^a   Krishnan, Sunil ^a   Liao, Zhongxing ^a   Liu, Ping ^a   Mao, Li ^a,b   Shi, Qiuling ^a   Mobley, Gary M ^a   Woodruff, Jeanie F ^a   Cleeland, Charles S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

Cancer; Chemoradiation; Colorectal cancer; Cytokines; Esophageal cancer; Fatigue; Inflammation; MDASI; Sickness behavior; Symptoms

Indexed keywords

HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR RECEPTOR 1; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGE; APPETITE DISORDER; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COLORECTAL CANCER; CORRELATIONAL STUDY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DISTRESS SYNDROME; DROWSINESS; DRUG USE; DYSPHAGIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; FATIGUE; FEMALE; GENDER; GENE OVEREXPRESSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIATION DOSE; RADIATION INJURY; RADIATION SITE SORENESS; SLEEP DISORDER; TREATMENT DURATION;

AGED; ANTINEOPLASTIC AGENTS; BODY MASS INDEX; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CYTOKINES; DATA INTERPRETATION, STATISTICAL; EATING DISORDERS; ESOPHAGEAL NEOPLASMS; FATIGUE; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RADIOTHERAPY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; REGRESSION ANALYSIS; SLEEP DISORDERS; SOCIOECONOMIC FACTORS; STRESS, PSYCHOLOGICAL;

EID: 84862789945     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2011.12.007     Document Type: Article

References (30)

1. Barsevick A.M., Cleeland C.S., Manning D.C., O'Mara A.M., Reeve B.B., Scott J.A., Sloan J.A. ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials. J. Pain Symptom Manage. 2010, 39:1086-1099.
2. Bower J.E., Ganz P.A., Irwin M.R., Arevalo J.M., Cole S.W. Fatigue and gene expression in human leukocytes: increased NF-kappaB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav. Immun. 2011, 25:147-150.
3. Bower J.E., Ganz P.A., Irwin M.R., Kwan L., Breen E.C., Cole S.W. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?. J. Clin. Oncol. 2011, 29:3517-3522.
4. Bower J.E., Ganz P.A., Tao M.L., Hu W., Belin T.R., Sepah S., Cole S., Aziz N. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin. Cancer Res. 2009, 15:5534-5540.
5. Chambers J.M., Cleveland W.S., Kleiner B., Tukey P.A. Graphical Methods for Data Analysis 1983, Wadsworth International Group, Belmont CA.
6. Cleeland C.S. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J. Natl. Cancer Inst. Monogr. 2007, 37:16-21.
7. Cleeland C.S., Bennett G.J., Dantzer R., Dougherty P.M., Dunn A.J., Meyers C.A., Miller A.H., Payne R., Reuben J.M., Wang X.S., Lee B.N. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism?. Cancer 2003, 97:2919-2925.
8. Cleeland C.S., Mendoza T.R., Wang X.S., Chou C., Harle M.T., Morrissey M., Engstrom M.C. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000, 89:1634-1646.
9. Collado-Hidalgo A., Bower J.E., Ganz P.A., Cole S.W., Irwin M.R. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin. Cancer Res. 2006, 12:2759-2766.
10. Couzin-Frankel J. Inflammation bares a dark side. Science 2010, 330:1621.
11. Dantzer R. Cytokine-induced sickness behavior: where do we stand?. Brain Behav. Immun. 2001, 15:7-24.
12. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
13. Greenberg D.B., Gray J.L., Mannix C.M., Eisenthal S., Carey M. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J. Pain Symptom Manage. 1993, 8:196-200.
14. Hart J.P., Broadwater G., Rabbani Z., Moeller B.J., Clough R., Huang D., Sempowski G.A., Dewhirst M., Pizzo S.V., Vujaskovic Z., Anscher M.S. Cytokine profiling for prediction of symptomatic radiation-induced lung injury. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:1448-1454.
15. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71:171-186.
16. Inagaki M., Isono M., Okuyama T., Sugawara Y., Akechi T., Akizuki N., Fujimori M., Mizuno M., Shima Y., Kinoshita H., Uchitomi Y. Plasma interleukin-6 and fatigue in terminally ill cancer patients. J. Pain Symptom Manage. 2008, 35:153-161.
17. Lee B.N., Dantzer R., Langley K.E., Bennett G.J., Dougherty P.M., Dunn A.J., Meyers C.A., Miller A.H., Payne R., Reuben J.M., Wang X.S., Cleeland C.S. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. NeuroImmunoModulation 2004, 11:279-292.
18. Miller A.H., Ancoli-Israel S., Bower J.E., Capuron L., Irwin M.R. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J. Clin. Oncol. 2008, 26:971-982.
19. Monk J.P., Phillips G., Waite R., Kuhn J., Schaaf L.J., Otterson G.A., Guttridge D., Rhoades C., Shah M., Criswell T., Caligiuri M.A., Villalona-Calero M.A. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J. Clin. Oncol. 2006, 24:1852-1859.
20. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982, 5:649-655.
21. Ong Z.Y., Gibson R.J., Bowen J.M., Stringer A.M., Darby J.M., Logan R.M., Yeoh A.S., Keefe D.M. Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat. Oncol 2010, 5:22.
22. Orre I.J., Murison R., Dahl A.A., Ueland T., Aukrust P., Fosså S.D. Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain Behav. Immun. 2009, 23:868-874.
23. Park H.C., Janjan N.A., Mendoza T.R., Lin E.H., Vadhan-Raj S., Hundal M., Zhang Y., Delclos M.E., Crane C.H., Das P., Wang X.S., Cleeland C.S., Krishnan S. Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75:775-781.
24. Reinertsen K.V., Grenaker Alnæs G.I., Landmark-Høyvik H., Loge J.H., Wist E., Kristensen V.N., Fosså S.D., Edvardsen H. Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway. Brain Behav. Immun. 2011, 25:1376-1383.
25. Rich T., Innominato P.F., Boerner J., Mormont M.C., Iacobelli S., Baron B., Jasmin C., Lévi F. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin. Cancer Res. 2005, 11:1757-1764.
26. Schubert C., Hong S., Natarajan L., Mills P.J., Dimsdale J.E. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav. Immun. 2007, 21:413-427.
27. Wang X.S. Pathophysiology of cancer-related fatigue. Clin. J. Oncol. Nurs. 2008, 12:11-20.
28. Wang X.S., Fairclough D.L., Liao Z., Komaki R., Chang J.Y., Mobley G.M., Cleeland C.S. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J. Clin. Oncol. 2006, 24:4485-4491.
29. Wang X.S., Shi Q., Williams L.A., Cleeland C.S., Mobley G.M., Reuben J.M., Lee B.N., Giralt S.A. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer 2008, 113:2102-2109.
30. Wang X.S., Shi Q., Williams L.A., Mao L., Cleeland C.S., Komaki R.R., Mobley G.M., Liao Z. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav. Immun. 2010, 24:968-974.